C. elegans Point Mutation Service
Our Point Mutation service uses CRISPR/Cas9, which is the best gene editing method for creating small, precise edits to introduce a small number of nucleotide changes at a target site. With this service you can:
- study a disease-causing mutation
- humanize a critical amino acid
- explore the binding site of an enzyme
- introduce phosphomimetics
- mutate isoform start sites or make any specific mutation of interest.
Our CRISPR/Cas9 editing is typically very efficient. Among the F1 candidates with the Co-CRISPR edit, our average percentage of animals with the target edit was 65.7%. Edit percentages as high as 95% were observed.
96 point mutations in 1 gene. All 96 mutations were created in the STXBP1 gene (which is associated with epilepsy in humans) via CRISPR. The worm homolog of STXBP1, unc-18, causes uncoordination and near-complete lack of pharyngeal pumping when knocked out. The functionality is restored by replacing the worm gene with the coding sequence for human STXBP1.
Service Details (price reflects academic pricing)
|Service Package||Price||Est. Delivery Time|
|Full Build||$4,075 - $4,360||6 - 8 Weeks|
|Candidate Lines||$2,554 - $2,839||3 - 4 Weeks|
|Custom Injection Mix||$995 - $1,295||1 - 2 Weeks|
Point Mutation Publications
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
Sangeetha Iyer, Feba S. Sam, Nina DiPrimio, Graeme Preston, Jan Verheijen, Kausalya Murthy, Zachary Parton, Hillary Tsang, Jessica Lao, Eva Morava2 and Ethan O. Perlstein. Disease Models & Mechanisms (2019) 12.